Molinari A C, Castagnola E, Mazzola C, Piacentino M, Fratino G
Department of Oncology and Haematology, Giannina Gaslini Institute, Genova, Italy.
Support Care Cancer. 2001 Oct;9(7):539-44. doi: 10.1007/s005200100237.
Indwelling central venous catheters (CVC) are essential devices in the management of children with oncological/haematological diseases being treated with chemotherapy or undergoing bone marrow transplantation. Our study was aimed at detecting the incidence of important thrombotic events caused by CVC in children, and the coexistence of coagulation disorders in children affected with thromboembolic disease related to CVC. Therefore, we describe some antithrombotic strategies which have been successfully applied to solve functioning problems of correctly inserted CVC. We retrospectively evaluated the clinical records of 308 children (age range 2 months to 14 years) with oncological/haematological diseases undergoing insertion of 362 indwelling CVC from January 1994 to December 1998 at the Gaslini Children's Hospital. We collected data on seven serious asymptomatic thrombotic episodes diagnosed between 1994 and 1998 following catheter malfunctioning and one case of suspected lung embolism with symptoms. Coagulation tests allowed us to identify one case of probable heterozygosis of Protein C deficiency and one case of G20210A prothrombotic prothrombin mutation. This finding suggests the need for further evaluation for thrombophilia in all patients presenting with thrombotic complications of CVC. We therefore emphasise the importance of prophylaxis with low-dose heparin in children with malignancies receiving CVC. A prospective study, which has already been started, should identify the exact role of thromboembolic complications in children with indwelling CVC for oncological/ haematological malignancies.
中心静脉留置导管(CVC)是治疗接受化疗或进行骨髓移植的肿瘤/血液疾病患儿的重要设备。我们的研究旨在检测儿童CVC引发的重要血栓事件的发生率,以及患有与CVC相关的血栓栓塞性疾病的儿童中凝血障碍的共存情况。因此,我们描述了一些已成功应用于解决正确插入的CVC功能问题的抗血栓策略。我们回顾性评估了1994年1月至1998年12月在加斯利尼儿童医院接受362根中心静脉留置导管插入术的308名肿瘤/血液疾病患儿(年龄范围2个月至14岁)的临床记录。我们收集了1994年至1998年间导管故障后诊断出的7例严重无症状血栓形成事件以及1例有症状的疑似肺栓塞病例的数据。凝血测试使我们确定了1例可能的蛋白C缺乏杂合子病例和1例G20210A促血栓形成凝血酶原突变病例。这一发现表明,对于所有出现CVC血栓并发症的患者,需要进一步评估是否存在易栓症。因此,我们强调在接受CVC的恶性肿瘤患儿中使用低剂量肝素进行预防的重要性。一项已经启动的前瞻性研究应确定中心静脉留置导管在肿瘤/血液恶性肿瘤患儿中血栓栓塞并发症的确切作用。